The Cardiovascular Market Outlook to 2016

Introduction

The large number of impending patent expirations of blockbuster drugs will negatively impact the cardiovascular pharmaceutical segment. Evolving strategies in this segment such as in-licensing of drug candidates, and marketing of authorized generics, along with the development of first-in-line novel therapeutics might offset the effects of genericization.

Features and benefits

* Gain an overview of the cardiovascular market, including analyses of the disease subcategories, market sizing, market forecasts, and growth drivers.
* Develop insights into the R&D pipeline of leading pharmaceutical companies, and compare the prospects for individual pipeline drugs.
* Assess the innovative first-in-class drugs in the various therapeutic subcategories, and judge their future market potential.
* Reviewthe marketed product portfolio of the key players in this segment, and gain insights into the strategies that fuel their growth.
* Examine the epidemiology of major cardiovascular indications, and assess the major risk factors and prevalence forecasts to 2016.

Highlights

Cardiovascular diseases encompass a range of ailments such as hypertension, dyslipidemia, stroke, atherosclerosis, thrombosis, and coronary artery disease. Dyslipidemia was the indication with the highest reported prevalence in 2010 with an estimated 336 million cases in the seven major markets.
Antidyslipidemic drugs occupied 18% of the cardiovascular segment in 2010. The entry of Lipitor generics in 2011 is expected to negatively impact future prospects of sales in this segment. Dalcetrapib, a CETP inhibitor, manufactured by Roche, is a potential blockbuster in this segment that could offset the negative impact of genericization.
Antithrombotics recorded strong sales in 2010, and occupied a market share of 11%. This segment is forecast to deliver strong growth in the next two years owing to the commercialization of recently approved products such as Pradaxa and Xarelto and the expected launch of Pfizer/BMS’s apixaban in the US.

Your key questions answered

* What are the key growth drivers and resistors that will affect various therapeutic sub-categories of the cardiovascular market?
* What are the novel therapeutics being developed in the cardiovascular segment, and which of these offer significant potential for future growth?
* What are the various R&D strategies of top pharmaceutical companies, and how do these strategies help in cost containment and sustenance of growth?
* What are the key brands in the various therapeutic subcategories, and which of these are likely to enjoy significant growth in future?
* How have the leading players built a strong position in the cardiovascular segment and what are their growth strategies?
[Studien Infos ausblenden]

Executive Summary
Overview and epidemiology of cardiovascular disorders
Global market analysis
Pipeline analysis
Competitive landscape
About Business Insights
Disclaimer
Overview and epidemiology of cardiovascular disorders
Summary
Introduction
Risk factors
Predisposing risk factors
Modifiable risk factors
Hypertension
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology
Dyslipidemia
Diagnosis, treatment, and management
Epidemiology
Forecast epidemiology
Cardiovascular diseases
Arteriosclerosis/atherosclerosis
Thrombosis
Cardiac arrhythmias
Myocardial infarction (MI)
Acute coronary syndrome (ACS)
Congestive heart failure (CHF)
Coronary artery disease (CAD)
Peripheral artery disease (PAD)
Pulmonary hypertension
Angina pectoris
Stroke
Epidemiology
Forecast epidemiology
Global market analysis
Summary
Introduction
Market analysis by geography
Key events in the cardiovascular market
European approval for Rasilamlo
BMS/Pfizer’s apixaban likely to receive EU approval
Angiotensin receptor blockers (ARBs) may cause increased cancer risk
Crestor’s patent upheld in the US
Plavix boxed warning for poor metabolizers
Market analysis by drug class
Antihypertensives
Introduction
Antihypertensive drug classes
Leading treatment brands by drug class
Key brands analysis
Antidyslipidemics
Introduction
Antidyslipidemic drug classes
Leading treatment brands by drug class
Key brands analysis
Future blockbusters in the antidyslipidemic drug class
Antithrombotics
Introduction
Antithrombotics drug classes
Leading treatment brands by drug class
Key brands analysis
Future blockbusters in the antithrombotic drug class
Other cardiovascular agents
Introduction
Leading treatment brands by drug class
Tracleer
Leading brands dynamics and sales forecasts
Product growth-share matrix for leading brands
Pipeline analysis
Summary
Introduction
Key events in the cardiovascular market
First advanced therapy certificate for t2cure’s somatic cell therapy
Clear evidence of safety leads to termination of apixaban’s Phase III AVERROES trial
FDA panel to review AstraZeneca’s Brilinta
Novartis presents successful Phase II results of LCZ696
Daiichi Sankyo’s CS-8635 shows promising results in pivotal trial
Sanofi (Genzyme)/Isis’ mipomersen clears second Phase III trial, but raises safety concerns
Cardiovascular pipeline
Leading drugs in development
Profiles of key pipeline products
Key antihypertensive pipeline drugs
Key antidyslipidemic pipeline drugs
Key antithrombotic pipeline drugs
Competitive landscape
Summary
Introduction
Competitive positioning of top players in the cardiovascular market
Pfizer
Overview
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Sanofi
Overview
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
AstraZeneca
Overview
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Novartis
Overview
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Bristol-Myers Squibb (BMS)
Overview
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Merck
Overview
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Appendix
Scope and methodology
Scope
Methodology
Abbreviations
References
[Inhaltsverzeichnis ausblenden]